AI Insight
A new study found that four weeks of low-dose rapamycin, an anti-aging drug, improved brain blood flow in healthy middle-aged adults carrying the APOE4 gene variant, which increases Alzheimer's disease risk. Women showed particularly strong benefits from the treatment. Since reduced cerebral blood flow can occur years before Alzheimer's symptoms emerge, this intervention may offer a potential preventive approach for at-risk individuals.
Why it matters
This research suggests a possible strategy to prevent or delay Alzheimer's disease by targeting early physiological changes before cognitive symptoms appear. If confirmed in larger trials, rapamycin could become a preventive treatment for people genetically predisposed to Alzheimer's, particularly women with the APOE4 variant.
Understand the Science
A surprising new study suggests that an anti-aging drug could help protect people genetically predisposed to Alzheimer’s disease. Researchers found that just four weeks of low-dose rapamycin improved brain blood flow in healthy middle-aged adults carrying the high-risk APOE4 gene variant, with women showing the strongest benefits. Because declining blood flow can occur years before Alzheimer’s symptoms appear, the discovery raises hopes for preventing or delaying the disease before memory loss begins.
Source: An anti-aging drug may help protect the brain before Alzheimer's symptoms begin